Rituximab is an anti-CD20 monoclonal antibody that suppresses inflammation effectively in autoimmune diseases. It was initially approved by the FDA for the treatment of B-cell lymphomas and later ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

Rituximab-induced interstitial lung disease in patients with non-Hodgkin lymphoma presents with distinct clinical characteristics and bronchoalveolar lavage results. “These findings enhance the ...

Acquired factor V (FV) inhibitors are extremely rare and present with a broad spectrum ranging from asymptomatic laboratory anomalies to life-threatening critical bleeds. The overall rarity along with ...

Switching to biosimilars when treating patients with haematological cancers does not increase the risk of adverse events, ...